PARIS, FRANCE — July 5, 2002 —
Treatment with a three-dose infliximab induction regimen produces rapid clearance in the treatment of moderate to severe plaque psoriasis and is associated with a durable response through 26 weeks, a recent extension study has found.
Dr. Alice Gottlieb, with the University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School in New Brunswick, New Jersey, United States, presented the results here today at the 20th World Congress of Dermatology (WCD). The data also show that infliximab is safe and well tolerated.
An earlier 10-week, double-blind, placebo-controlled trial of 33 patients with moderate to severe psoriasis demonstrated that infliximab was well tolerated and provided substantial clinical benefit without significant toxicity. Twenty-one patients responded to treatment: nine of 11 receiving infliximab 5 mg/kg, 10 of 11 receiving infliximab 10 mg/kg, and two of 11 receiving placebo. Responders achieved a good, excellent, or clear rating on physician global assessment at week 10. A greater than 75 percent improvement in the Psoriasis Area Severity Index (PASI) score was observed for nine patients receiving infliximab 5 mg/kg, eight receiving infliximab 10 mg/kg, and two receiving placebo.
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!